Divyanshu Dubey, MBBS, Mayo Clinic, Rochester, MN, outlines the most promising research avenues for immunotherapy to treat autoimmune neurological disorders. Anti-neonatal Fc receptor (FcRn) monoclonal antibodies have the potential to revolutionize the field of autoimmune neurology. Clinical trials have shown encouraging results in myasthenia gravis, and further studies are investigating their use in other autoimmune conditions. Complement inhibitors are also crucial in complement-mediated autoimmune diseases. Notably, a better understanding of the disease mechanisms will help tailor the available treatment regimens to each patient. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Dr Dubey has consulted for UCB, Immunovant and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. Dr Dubey has patents pending for Kelch-like protein 11 (KLHL11) IgG and Leucine Zipper 4 (LUZP4) IgG as markers of neurological autoimmunity.